Close this search box.

NBA EHL treatment tender announced!

The National Blood Authority (NBA) has announced the outcome of its recent tender process for extended half life clotting factor products today. You will see the relevant document on the NBA website.

This means that there is funded access to extended half life factor VIII for all people with haemophilia A and an extended half life factor IX for all people with haemophilia B where they and their treating doctor at their Haemophilia Treatment Centre consider it for their treatment. Due to COVID-19 and some other local reasons there may be some delays to access; however, those who have been waiting for this development should speak with their doctor at their Haemophilia Treatment Centre. 

This announcement does not include a decision about government funding for Hemlibra (emicizumab) which is registered in Australia for the treatment of people with severe and moderate haemophilia A with and without inhibitors. Hemlibra is not on the National Product List. HFA will continue to advocate for Hemlibra to be funded as well as the products on this list for our community. 

Latest stories

Men’s Health Week 2024

International Men’s Health Week runs each year in the middle of June. It is an important opportunity to highlight the importance of men’s health, and to promote and support the health and wellbeing of men and boys in our communities.

Read More

Paul talks about his career

Paul shares his experience working as an apprentice shipwright and boat builder, a FIFO WHS manager, and today supporting his brother in a business with over 60 employees and a growing client base.

Read More
Skip to content